KB001-A: Completed Phase II enrollment

KaloBios completed enrollment of 180 patients with CF with chronic P. aeruginosa lung infection in a double-blind, placebo-controlled, international Phase II trial evaluating IV KB001-A. KB001-A has Orphan Drug designation in the U.S. and EU for the indication and Fast Track designation in the U.S. to prevent bacterial pneumonia caused by P. aeruginosa in mechanically ventilated patients (see BioCentury, May 6, 2013 & Nov. 4, 2013). ...